Zhejiang Jasan Holding Group Co Ltd

Jiansheng Group announced on the evening of September 11 that as of September 10, the company had repurchased a cumulative 20.0886 million shares through centralized bidding, accounting for 5.86 percent of its current total share capital. The highest transaction price was 14.55 yuan per share and the lowest was 10.27 yuan per share, with cumulative funds paid totaling approximately 234 million yuan including transaction fees. The announcement showed that the company held the twenty-first meeting of the sixth board of directors on September 18, 2025, and convened the fifth extraordinary shareholders' meeting of 2025 on October 10 of the same year, at which the repurchase plan was reviewed and approved. The plan agreed to use its own funds and a special stock repurchase loan from China CITIC Bank to repurchase shares through centralized bidding, with total repurchase funds not exceeding 300 million yuan and not less than 150 million yuan, a repurchase price not exceeding 14.69 yuan per share, and a repurchase period from October 10, 2025 to October 9, 2026. The company carried out its first repurchase on October 15, 2025. The company stated that it will strictly implement repurchases within the repurchase period based on market conditions in accordance with relevant regulations, and fulfill its information disclosure obligations in a timely manner.

Several A-share companies disclosed progress on share buybacks. Among them, Zhongji Innolight repurchased 374,100 shares on the first day after announcing a planned buyback of up to 8 billion yuan, paying a total of 318 million yuan. As of August 31, China Petroleum and Chemical Corporation had cumulatively repurchased 104 million A-shares for a total of 500 million yuan; Jiuzhou Pharmaceutical had repurchased 15.41 million shares for 212 million yuan; MGI Tech had repurchased 2.01 million shares for about 100 million yuan; Double Medical Technology had repurchased 6.21 million shares for 260 million yuan; Jiansheng Group had repurchased 19.25 million shares for 224 million yuan; and Bear Electric Appliance had repurchased 1.95 million shares for 65.95 million yuan.

Jiansheng Group released its 2026 interim report, with net profit attributable to the parent company at 175 million yuan, an increase of 23.23% over the same period last year. Total operating revenue was 1.211 billion yuan, up 3.40% year-on-year, marking three consecutive years of growth. Net cash inflow from operating activities was 114 million yuan, down 54.94% year-on-year. The latest asset-liability ratio stands at 42.93%, gross margin at 30.46%, ROE at 7.80%, and diluted earnings per share at 0.53 yuan.

According to statistics from Securities Times Data Treasure, a total of 13 companies released their 2026 semi-annual reports on August 4. Among them, Jinyu Bio posted the largest profit increase, with net profit up 72.28 percent year-on-year. Jinyu Bio achieved net profit of 104 million yuan and operating revenue of 756 million yuan, up 22.09 percent. WuXi AppTec reported net profit of 11.08 billion yuan, up 29.43 percent, on operating revenue of 28.897 billion yuan, up 38.93 percent. Companies such as Jasan Group, Sinocare, Sihui Fushi, and Wanda Bearing also recorded net profit growth, while seven companies including Jiahuan Technology and Sinodata saw net profit decline year-on-year.

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.